The recent lack of efficacy in HIV vaccine efficacy trials has spurred a shift towards discovery-based preclinical studies and small discovery medicine clinical trials, focusing on innovative strategies to elicit bNAbs. Key aspects of this promising approach to HIV vaccine development include leveraging the natural evolution of the immune response by guiding naïve B cell precursors through an affinity maturation process to develop potent bNAbs capable of neutralizing diverse HIV strains.
Building on foundational knowledge from previous events on basic research, this webinar, organized by the Global HIV Vaccine Enterprise at IAS – the International AIDS Society – and the Duke Human Vaccine Institute, shifts focus to more advanced HIV-1 vaccine candidates and translational strategies and highlights clinical trial findings and preclinical studies that evaluate innovative immunogens and vaccine platforms.
